MA26868A1 - Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases - Google Patents

Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases

Info

Publication number: MA26868A1
Authority: MA; Morocco
Prior art keywords: group; unsubstituted; pregabalin; compounds; useful
Prior art date: 2000-01-25

Application number

MA26736A

Other languages

English (en)

French (fr)

Inventor

John Booth Richard

Myra Dobrusin Ellen

Laurence Toogood Peter

Prasad Venkata Nagendra J Vara

Joseph Mcnamara Dennis

Original Assignee

Warner Lambert Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-25

Filing date

2002-07-22

Publication date

2004-12-20

2002-07-22 Application filed by Warner Lambert Co filed Critical Warner Lambert Co

2004-12-20 Publication of MA26868A1 publication Critical patent/MA26868A1/fr

Links

108091000080 Phosphotransferase Proteins 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
102000020233 phosphotransferase Human genes 0.000 title 1
229960001233 pregabalin Drugs 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 3
AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 3
125000003342 alkenyl group Chemical group 0.000 abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 2
125000000304 alkynyl group Chemical group 0.000 abstract 2
125000004093 cyano group Chemical group *C#N 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
229910052739 hydrogen Inorganic materials 0.000 abstract 2
239000001257 hydrogen Substances 0.000 abstract 2
229940043355 kinase inhibitor Drugs 0.000 abstract 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
239000003757 phosphotransferase inhibitor Substances 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
101150020251 NR13 gene Proteins 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000028017 Psychotic disease Diseases 0.000 abstract 1
208000027520 Somatoform disease Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
238000009876 asymmetric hydrogenation reaction Methods 0.000 abstract 1
238000011914 asymmetric synthesis Methods 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
208000035269 cancer or benign tumor Diseases 0.000 abstract 1
125000000753 cycloalkyl group Chemical group 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
150000002431 hydrogen Chemical class 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
208000027753 pain disease Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
-1 pregabalin Pyrido [2,3-d] pyrimidine-2,7-diamines Chemical class 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000023516 stroke disease Diseases 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Enzymes And Modification Thereof (AREA)

MA26736A 2000-01-25 2002-07-22 Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases MA26868A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US17826100P	2000-01-25	2000-01-25

Publications (1)

Publication Number	Publication Date
MA26868A1 true MA26868A1 (fr)	2004-12-20

Family

ID=22651853

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA26736A MA26868A1 (fr)	2000-01-25	2002-07-22	Pyrido[2,3-d]pyrimidine-2,7-diamines inhibitrices de kinases

Country Status (34)

Country	Link
EP (1)	EP1254137A1 (is)
JP (1)	JP4047010B2 (is)
KR (1)	KR20020065939A (is)
CN (1)	CN1395578A (is)
AP (1)	AP2002002586A0 (is)
AR (1)	AR030044A1 (is)
AU (1)	AU2542501A (is)
BG (1)	BG106850A (is)
BR (1)	BR0107751A (is)
CA (1)	CA2397961C (is)
CO (1)	CO5261549A1 (is)
CR (1)	CR6706A (is)
CZ (1)	CZ20022475A3 (is)
DZ (1)	DZ3266A1 (is)
EA (1)	EA200200643A1 (is)
EE (1)	EE200200405A (is)
GT (1)	GT200100016A (is)
HN (1)	HN2001000013A (is)
HU (1)	HUP0204141A3 (is)
IL (1)	IL150545A0 (is)
IS (1)	IS6443A (is)
MA (1)	MA26868A1 (is)
MX (1)	MXPA02007221A (is)
NO (1)	NO20023527L (is)
OA (1)	OA12161A (is)
PA (1)	PA8510701A1 (is)
PE (1)	PE20011066A1 (is)
PL (1)	PL356802A1 (is)
SK (1)	SK10632002A3 (is)
SV (1)	SV2002000294A (is)
TN (1)	TNSN01014A1 (is)
WO (1)	WO2001055147A1 (is)
YU (1)	YU50402A (is)
ZA (1)	ZA200205879B (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7235551B2 (en)	2000-03-02	2007-06-26	Smithkline Beecham Corporation	1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
EP2404603A1 (en)	2000-10-23	2012-01-11	Glaxosmithkline LLC	Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
PE20030008A1 (es) *	2001-06-19	2003-01-22	Bristol Myers Squibb Co	Inhibidores duales de pde 7 y pde 4
MXPA04010267A (es)	2002-04-19	2005-02-03	Smithkline Beecham Corp	Compuestos novedosos.
KR20050084027A (ko) *	2002-11-28	2005-08-26	쉐링 악티엔게젤샤프트	Ｃｈｋ-, ｐｄｋ- 및 ａｋｔ-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
US7157455B2 (en) *	2003-02-10	2007-01-02	Hoffmann-La Roche Inc.	4-Aminopyrimidine-5-one derivatives
TW200502236A (en) *	2003-03-28	2005-01-16	Hoffmann La Roche	Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr)	2004-07-15	2007-11-23	Sanofi Synthelabo	Derives de pyrido-pyrimidine, leur application en therapeutique
US7550589B2 (en) *	2004-09-21	2009-06-23	Hoffman-La Roche Inc.	6-(2-alkyl-phenyl)-pyrido[2,3-D]pyrimidines useful as protein kinase inhibitors
PE20061351A1 (es)	2005-03-25	2007-01-14	Glaxo Group Ltd	COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
US20090137550A1 (en)	2005-03-25	2009-05-28	Glaxo Group Limited	Novel Compounds
TW200724142A (en)	2005-03-25	2007-07-01	Glaxo Group Ltd	Novel compounds
EP1865959A2 (en)	2005-03-25	2007-12-19	Glaxo Group Limited	Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
FR2887882B1 (fr) *	2005-07-01	2007-09-07	Sanofi Aventis Sa	Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
WO2007009911A1 (en) *	2005-07-21	2007-01-25	F. Hoffmann-La Roche Ag	PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
AU2006279992A1 (en)	2005-08-09	2007-02-22	Irm Llc	Compounds and compositions as protein kinase inhibitors
FR2896246B1 (fr)	2006-01-13	2008-08-15	Sanofi Aventis Sa	Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en)	2006-10-16	2008-04-23	GPC Biotech Inc.	Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar)	2006-12-20	2016-09-05	Takeda Pharmaceuticals Co	مثبطات كينازmapk/erk
FR2910813B1 (fr) *	2006-12-28	2009-02-06	Sanofi Aventis Sa	Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en)	2008-04-22	2013-10-16	Forma Therapeutics, Inc.	Improved raf inhibitors
EA201100879A1 (ru) *	2008-12-01	2012-01-30	Мерк Патент Гмбх	Производные пиридопиримидина в качестве ингибиторов аутотаксина
GB201104267D0 (en)	2011-03-14	2011-04-27	Cancer Rec Tech Ltd	Pyrrolopyridineamino derivatives
GB201216017D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Inhibitor compounds
GB201216018D0 (en)	2012-09-07	2012-10-24	Cancer Rec Tech Ltd	Pharmacologically active compounds
EP3733184B1 (en) *	2013-03-14	2023-08-30	Icahn School of Medicine at Mount Sinai	Pyrimidine compounds for use in the treatment of cancer
GB201403536D0 (en)	2014-02-28	2014-04-16	Cancer Rec Tech Ltd	Inhibitor compounds
KR101671404B1 (ko) *	2014-09-02	2016-11-02	한국원자력의학원	항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) *	2016-04-11	2019-07-02	上海勋和医药科技有限公司	杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en)	2017-06-20	2017-08-02	Inst Of Cancer Research: Royal Cancer Hospital	Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL115256A0 (en) *	1994-11-14	1995-12-31	Warner Lambert Co	6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
MX9702245A (es) *	1994-11-14	1997-06-28	Warner Lambert Co	Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
US5620981A (en) *	1995-05-03	1997-04-15	Warner-Lambert Company	Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EE200000706A (et) *	1998-05-26	2002-06-17	Warner-Lambert Company	Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid

2001
- 2001-01-23 WO PCT/IB2001/000069 patent/WO2001055147A1/en not_active Ceased
- 2001-01-23 EE EEP200200405A patent/EE200200405A/xx unknown
- 2001-01-23 YU YU50402A patent/YU50402A/sh unknown
- 2001-01-23 PA PA20018510701A patent/PA8510701A1/es unknown
- 2001-01-23 HU HU0204141A patent/HUP0204141A3/hu unknown
- 2001-01-23 DZ DZ013266A patent/DZ3266A1/fr active
- 2001-01-23 EA EA200200643A patent/EA200200643A1/ru unknown
- 2001-01-23 EP EP01900591A patent/EP1254137A1/en not_active Withdrawn
- 2001-01-23 AR ARP010100285A patent/AR030044A1/es not_active Application Discontinuation
- 2001-01-23 CZ CZ20022475A patent/CZ20022475A3/cs unknown
- 2001-01-23 SK SK1063-2002A patent/SK10632002A3/sk not_active Application Discontinuation
- 2001-01-23 CA CA002397961A patent/CA2397961C/en not_active Expired - Fee Related
- 2001-01-23 PE PE2001000072A patent/PE20011066A1/es not_active Application Discontinuation
- 2001-01-23 OA OA1200200213A patent/OA12161A/en unknown
- 2001-01-23 BR BR0107751-1A patent/BR0107751A/pt not_active IP Right Cessation
- 2001-01-23 JP JP2001561006A patent/JP4047010B2/ja not_active Expired - Fee Related
- 2001-01-23 GT GT200100016A patent/GT200100016A/es unknown
- 2001-01-23 MX MXPA02007221A patent/MXPA02007221A/es not_active Application Discontinuation
- 2001-01-23 AU AU25425/01A patent/AU2542501A/en not_active Abandoned
- 2001-01-23 PL PL01356802A patent/PL356802A1/xx not_active Application Discontinuation
- 2001-01-23 KR KR1020027009516A patent/KR20020065939A/ko not_active Ceased
- 2001-01-23 CN CN01804048A patent/CN1395578A/zh active Pending
- 2001-01-23 AP APAP/P/2002/002586A patent/AP2002002586A0/en unknown
- 2001-01-23 IL IL15054501A patent/IL150545A0/xx unknown
- 2001-01-24 CO CO01005268A patent/CO5261549A1/es not_active Application Discontinuation
- 2001-01-24 SV SV2001000294A patent/SV2002000294A/es not_active Application Discontinuation
- 2001-01-24 TN TNTNSN01014A patent/TNSN01014A1/fr unknown
- 2001-01-24 HN HN2001000013A patent/HN2001000013A/es unknown
2002
- 2002-06-20 BG BG106850A patent/BG106850A/bg unknown
- 2002-06-25 IS IS6443A patent/IS6443A/is unknown
- 2002-07-17 CR CR6706A patent/CR6706A/es not_active Application Discontinuation
- 2002-07-22 MA MA26736A patent/MA26868A1/fr unknown
- 2002-07-23 ZA ZA200205879A patent/ZA200205879B/en unknown
- 2002-07-24 NO NO20023527A patent/NO20023527L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TNSN01014A1 (fr)	2005-11-10
NO20023527L (no)	2002-09-10
PL356802A1 (en)	2004-07-12
CZ20022475A3 (cs)	2003-03-12
AP2002002586A0 (en)	2002-09-30
JP2003523357A (ja)	2003-08-05
WO2001055147A1 (en)	2001-08-02
EA200200643A1 (ru)	2002-12-26
CN1395578A (zh)	2003-02-05
EP1254137A1 (en)	2002-11-06
CA2397961C (en)	2008-08-26
YU50402A (sh)	2005-11-28
CA2397961A1 (en)	2001-08-02
NO20023527D0 (no)	2002-07-24
OA12161A (en)	2006-05-08
KR20020065939A (ko)	2002-08-14
BG106850A (bg)	2003-02-28
CO5261549A1 (es)	2003-03-31
DZ3266A1 (fr)	2001-08-02
HUP0204141A2 (hu)	2003-04-28
GT200100016A (es)	2001-10-19
AU2542501A (en)	2001-08-07
IL150545A0 (en)	2003-02-12
BR0107751A (pt)	2002-11-12
IS6443A (is)	2002-06-25
HUP0204141A3 (en)	2005-03-29
SV2002000294A (es)	2002-07-16
SK10632002A3 (sk)	2003-06-03
HN2001000013A (es)	2001-06-18
AR030044A1 (es)	2003-08-13
ZA200205879B (en)	2003-09-29
PA8510701A1 (es)	2002-12-11
CR6706A (es)	2005-04-04
MXPA02007221A (es)	2002-11-29
EE200200405A (et)	2003-12-15
PE20011066A1 (es)	2001-10-22
JP4047010B2 (ja)	2008-02-13

Publication	Publication Date	Title
TNSN04156A1 (fr)	2007-03-12	Pyridinones substituees servant de modulateurs de la map-kinase p38
TNSN05250A1 (fr)	2007-07-10	Pyrimidinones substituees
US7745646B2 (en)	2010-06-29	Bicyclic heteroaryl inhibitors of PDE4
MA27774A1 (fr)	2006-02-01	Inhibiteurs de phosphatidylinositol 3-kinase
JP7450559B2 (ja)	2024-03-15	疾患の処置のためのｋｄｍ１ａ阻害剤
TNSN05073A1 (fr)	2007-05-14	Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase
MA28064A1 (fr)	2006-08-01	Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases
TNSN05298A1 (fr)	2007-07-10	Derives de pyrazolo-quinazoline, procede pour leur preparation et leur utilisation comme inhibiteurs de kinases
MA26727A1 (fr)	2004-12-20	Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
BR0201087A (pt)	2003-05-27	Compostos antiinflamatórios de benzotriazol
MA26991A1 (fr)	2004-12-20	Triazolopyridines servant d'agents anti-inflammatoires
MA30360B1 (fr)	2009-04-01	Dérivés pyrimidiniques utilisés comme inhibiteurs de la pi3k
MA27438A1 (fr)	2005-07-01	Piperazines heterocycliques substituees pour le traitement de la schizophrenie
MA26718A1 (fr)	2004-12-20	Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
SI1678166T1 (sl)	2009-10-31	Inhibitorji proteinske kinaze
MA27568A1 (fr)	2005-10-03	Derives de pyrrolopyrimidine
MA31170B1 (fr)	2010-02-01	Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
MA27440A1 (fr)	2005-07-01	Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf)
TNSN01014A1 (fr)	2005-11-10	PYRIDO [2, 3-d] PYRIMIDINE-2, 7-DIAMINES INHIBITRICES DE KINASES, ET COMPOSITIONS LES CONTENANT
MA28742B1 (fr)	2007-07-02	Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique
WO2002078639A2 (en)	2002-10-10	A method of treating proliferative diseases using eg5 inhibitors
MA26701A1 (fr)	2004-12-20	PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
PL1725536T3 (pl)	2009-04-30	Pochodne imidazoliny mające czynność CB1-antagonistyczną
MA28429B1 (fr)	2007-02-01	Dérivés de 1H-thiéno [2,3-c] pyrazole utiles comme inhibiteurs de kinases
JP2020531574A (ja)	2020-11-05	化合物、その医薬組成物及びその使用及び応用